{"id":"mirabegron-with-vaginal-estrogen-cream","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Hypertension"},{"rate":"2-4%","effect":"Headache"},{"rate":"1-2%","effect":"Tachycardia"},{"rate":"1-5%","effect":"Vaginal irritation or discharge"},{"rate":"2-3%","effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mirabegron is a beta-3 adrenergic agonist that increases bladder capacity and reduces detrusor contractions, improving overactive bladder symptoms. Vaginal estrogen cream provides localized estrogen replacement to restore vaginal epithelial thickness, elasticity, and moisture, addressing genitourinary syndrome of menopause and urogenital atrophy. The combination addresses both the neurogenic bladder dysfunction and the underlying tissue atrophy contributing to lower urinary tract symptoms.","oneSentence":"Mirabegron relaxes bladder smooth muscle via beta-3 adrenergic receptor agonism, while vaginal estrogen cream restores local vaginal tissue health and reduces urogenital atrophy symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:23.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with urge incontinence"},{"name":"Genitourinary syndrome of menopause with urogenital atrophy"}]},"trialDetails":[{"nctId":"NCT06197295","phase":"PHASE4","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Urinary Bladder, Overactive, Effect of Drug","enrollment":200},{"nctId":"NCT06479720","phase":"PHASE4","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Effect of Drug, Urinary Bladder, Overactive","enrollment":300},{"nctId":"NCT05221021","phase":"PHASE4","title":"Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2022-10-01","conditions":"Overactive Bladder Syndrome","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Betmiga and Premarin"],"phase":"marketed","status":"active","brandName":"Mirabegron with vaginal estrogen cream","genericName":"Mirabegron with vaginal estrogen cream","companyName":"Mackay Memorial Hospital","companyId":"mackay-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirabegron relaxes bladder smooth muscle via beta-3 adrenergic receptor agonism, while vaginal estrogen cream restores local vaginal tissue health and reduces urogenital atrophy symptoms. Used for Overactive bladder with urge incontinence, Genitourinary syndrome of menopause with urogenital atrophy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}